Get the content you want anytime you want.
REGISTER NOW | SIGN IN

Healthcare professionals and thought leaders share their knowledge and insights on an array of infectious disease topics

Latest Videos

Fecal Transplantation in <i>Clostridium difficile</i>
Lawrence J. Brandt, MD; Erik Dubberke, MD; Daniel E. Freedberg, MD, MS; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, consider variables surrounding the use of fecal transplantation for the management of Clostridium difficile in select groups of patients.
Incorporating Technology into Antimicrobial Stewardship Programs
Debra Goff, PharmD, FCCP, explains how technology can be incorporated into antimicrobial stewardship programs.
Factors in Choosing Therapy for Gram-Negative NIs
Peter L. Salgo, MD; Sandy J. Estrada Lopez, PharmD, BCPS (AQID); Debra Goff, PharmD, FCCP; Andrew Shorr, MD; and Jason Pogue, PharmD, BCPS-AQID, reflect on which factors, such as a patient’s treatment history and clinical evidence behind a drug, are most important to consider when selecting a therapy to treat a gram-negative nosocomial infection.
High-Touch Points in Hospital Rooms That Harbor Pathogenic Bacteria
Barley Chironda, RPN, CIC, discusses different high-touch surfaces in hospital rooms that are known to harbor pathogenic bacteria.
Gram-Negative Nosocomial Infections: Systemic Risk
Peter L. Salgo, MD; Andrew Shorr, MD; Jason Pogue, PharmD, BCPS-AQID; Sandy J. Estrada Lopez, PharmD, BCPS (AQID); and Debra Goff, PharmD, FCCP, share insight on risk factors and systemic issues associated with long-term care settings that contribute to the formation of gram-negative nosocomial infections.
<i>Pseudomonas aeruginosa</i>: Current & Future Treatment Options
Marin H. Kollef, MD, discusses treatment options for Pseudomonas aeruginosa.
<i>Clostridium difficile</i>: The Role of Bezlotoxumab
Lawrence J. Brandt, MD; Erik Dubberke, MD; Daniel E. Freedberg, MD, MS; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, introduce bezlotoxumab, an additional treatment option that is in the pipeline for Clostridium difficile; explore how it works; and suggest which types of patients may be most appropriate to receive this treatment.
The Escalating Problem & Cost of Antimicrobial Resistance
Glenn Tillotson, PhD, FIDSA, provides insight into the growing problem and cost of antimicrobial resistance.
FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.